Business context and reporting period
Tonix Pharmaceuticals Holding Corp. filed this unaudited Form 10-Q for the quarter ended March 31, 2013. The company is a development-stage CNS-focused pharmaceutical business with no commercial products or revenue. Its lead candidate, TNX-102 SL (sublingual cyclobenzaprine), was being developed for fibromyalgia and post-traumatic stress disorder (PTSD). The filing’s share amounts reflect a 20-for-1 reverse stock split effected May 1, 2013.
Key financial metrics
| Metric | Q1 2013 / March 31, 2013 | Comparable period / December 31, 2012 |
|---|---|---|
| Revenue and cost of goods sold | $0 | $0 in Q1 2012 |
| Research and development expense | $740,629 | $397,628 in Q1 2012 |
| General and administrative expense | $1,260,596 | $762,737 in Q1 2012 |
| Operating loss | $2,001,225 | $1,160,365 in Q1 2012 |
| Net loss | $2,001,203; $0.93 per share | $2,014,988; $1.27 per share in Q1 2012 |
| Cash and restricted cash | $423,739 and $60,289 | $1,785,390 and $60,267 at December 31, 2012 |
| Working capital | Deficit of $725,358 | Not stated for December 31, 2012 |
| Total liabilities | $1,234,212 | $1,158,502 at December 31, 2012 |
| Cash used in operating activities | $1,361,629 | $1,777,614 in Q1 2012 |
Gross margin is not applicable because there were no sales. The balance sheet reports current liabilities of $1,216,788, principally accounts payable of $870,096 and accrued expenses of $346,692; it lists no current borrowings. The filing does not provide a clear debt balance beyond the liabilities shown. No cash was raised from financing activities in Q1 2013. The reported net loss was nearly unchanged year over year, despite higher operating expenses, largely because Q1 2012 included substantial financing costs.
Material changes versus the prior comparable period
- R&D expense increased 86% to $740,629, primarily from increased TNX-102 SL formulation, manufacturing, regulatory, and clinical-development work.
- G&A expense increased 65% to $1,260,596. Payroll-related expense rose, including $392,323 of noncash stock-based compensation; investor and public-relations costs also increased substantially.
- Operating cash use decreased to $1,361,629 from $1,777,614, but cash fell by $1,361,651 during the quarter to $423,739.
- Q1 2012 included $901,646 of interest and other financing costs, while Q1 2013 reported $22 of interest income. The prior-year period also included a $47,023 gain from a warrant-liability fair-value adjustment.
Outlook, risks, contingencies, and unusual items
- Management expected existing cash to cover operating and capital-equipment needs for approximately three months and estimated approximately $2.5 million would be needed for the next 12 months. Additional financing was required, with no existing financing commitments or available credit facilities.
- The filing and the auditor’s prior report identified substantial doubt about the company’s ability to continue as a going concern. If financing is unavailable or unacceptable, Tonix may need to cut costs, delay or reduce development, cease operations, or seek partners and potentially relinquish product rights.
- Management expected losses and R&D spending to increase, including over the next 12–24 months. Planned milestones were a potential fibromyalgia Phase 2b trial in Q3 2013, an IND filing for PTSD in Q3 2013, and a PTSD proof-of-concept trial in Q4 2013—all subject to funding and other uncertainties. TNX-201 and possibly TNX-301 formulation work was anticipated during 2013, with clinical trials not expected before 2014.
- Clinical, safety, patient-recruitment, regulatory, competition, and financing risks could delay or prevent development or approval; the company gave no assurance that any candidate would be approved or commercially viable.
- Subsequent events: on April 26, 2013, the company issued 38,334 shares for $306,667 upon warrant exercises. As of May 6, 2013, 2,197,490 common shares were outstanding.
- Management reported disclosure controls effective at a reasonable-assurance level and no material change in internal control over financial reporting during the quarter. The company reported no material legal proceedings.
Important facts for investors to verify
- Whether the company secured sufficient financing after the filing to fund operations and planned clinical programs.
- Actual cash burn, payable timing, and runway compared with management’s three-month cash estimate and $2.5 million 12-month funding need.
- Whether the planned TNX-102 SL fibromyalgia and PTSD milestones occurred, and the resulting clinical and regulatory outcomes.
- The dilution and share-count effects of warrant exercises, outstanding warrants and options, and the reverse split; reconcile the March 31 balance-sheet share count with the May 6 reported count.
- The effect of ongoing stock-based compensation and related-party consulting payments on reported expenses and cash needs.